SGEN : Analysis & Opinions

  1. Seattle Genetics Initiates Phase Ib Study on Leukemia Drug - ...

    December 19, 2014
    Seattle Genetics, Inc. (SGEN) has initiated a phase Ib study on SGN-CD33A for newly diagnosed acute myeloid leukemia.
  2. Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day

    December 18, 2014
    Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day
  3. Target And Others Insiders Have Been Buying

    June 8, 2014
    Kinder Morgan, Seattle Genetics and Target are among the companies that have seen insider buying recently. Insiders may sell ...
  4. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  5. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  6. SGEN/Takeda's Adcetris Progresses - Analyst Blog

    January 25, 2013
    Seattle Genetics Inc. (SGEN) and Takeda Pharmaceutical Company Limited (TKPYY) recently announced the commencement of a global ...
  7. 2 Global Funds with a Large-Cap Tilt

    August 19, 2011
    Joe Pitzl and Jason Good say retail investors can benefit from some exposure to large caps, including global stocks. They ...
Trading Center